Journals / Sakarya Tıp Dergisi / 2019 / Cilt: 9 - Sayı: 3

The Relationship Between Serum Urotensin II Level and Contrast-Induced Nephropathy and One-year Clinical Follow-up Findings in Patients with Coronary Slow Phenomenon Undergoing Percutaneous Coronary Intervention

Perkütan Koroner Girişim Yapılan Koroner Yavaş Akım Olgularında, Serum Urotensin II Düzeyi ve Kontrast Kaynaklı Nefropati Gelişimi ile Bir Yıllık Klinik Takip Bulguları Arasındaki İlişki

Pages
442–454
Publication Date
2019-09-16
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

One year clinical follow-up findings including all-cause mortality, cardiovascular death and MACE were significantly higher in CIN group, but stroke and myocardial infarction rates were similar in both groups.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Coronary slow-reflow phenomenon (CSFP) and Contrast-Induced Nephropathy (CIN) are associated with an increased risk of major cardiovascular adverse events.
📊
Key Findings & Data:This study aimed to evaluate the relationship between serum Urotensin II molecule (U-II) levels and CIN in patients with CSFP undergoing percutaneous coronary intervention (PCI).Methods: We enrolled 227 patients (161 male and 66 female; mean age: 61,44 ± 12,44 years) with angiographically diagnosed CSFP.
💡
Conclusion & Impact:One year clinical follow-up findings including all-cause mortality, cardiovascular death and MACE were significantly higher in CIN group, but stroke and myocardial infarction rates were similar in both groups.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Ürotensin II · Yavaş Akım Fenomeni · Kontrast Kaynaklı Nefropati

Abstract

Background: Coronary slow-reflow phenomenon (CSFP) and Contrast-Induced Nephropathy (CIN) are associated with an increased risk of major cardiovascular adverse events. This study aimed to evaluate the relationship between serum Urotensin II molecule (U-II) levels and CIN in patients with CSFP undergoing percutaneous coronary intervention (PCI).Methods: We enrolled 227 patients (161 male and 66 female; mean age: 61,44 ± 12,44 years) with angiographically diagnosed CSFP. The patients were divided into two groups according to CIN development (Non-CIN (n=206) and CIN group (n=21)). Results: CIN was observed in 9,25%(n=21) of the CSFP patients. Serum U-II level was significantly higher in CIN group than in non-CIN group (6,79±2,2 vs. 3±1,29, p<0.001). One year clinical follow-up findings including all-cause mortality (7(33,3%) vs. 24(11,7%), p=0,013), cardiovascular death(7(33,3%) vs. 18(8,7%), p=0,003) and Major Adverse cardiovascular events (MACE) (10(47,6%) vs. 46(22,4%), p: 0,011) were significantly higher in CIN group. We also performed forward conditional logistic regression analysis and found that U-II (Odds ratio (OR)= 3,983; 95% confidence interval (CI): 2,25 to 7,052; p < 0.001) and Mehran score (OR=1,228, 95% CI: 1,083-1,393, p=0,001) were independently predicted CIN development in patients with CSFP. Conclusions: Baseline serum U-II concentrations and higher Mehran scores are independently associated with CIN in CSFP patients. One year clinical follow-up findings including all-cause mortality, cardiovascular death and MACE were significantly higher in CIN group, but stroke and myocardial infarction rates were similar in both groups.

Özet

Amaç: Koroner yavaş akıntı fenomeni (CSFP) ve kontrast kaynaklı nefropati (CIN), artmış kardiyovasküler advers olay riski ile ilişkilidir. Bu çalışmada, CSFP'li perkütan koroner girişim (PCI) yapılan hastalarda serum Urotensin II molekülü (U-II) düzeyleri ile CIN arasındaki ilişkiyi değerlendirmeyi amaçladık. Yöntem: Anjiyografik olarak CSFP tanısı alan 227 hasta (161 erkek ve 66 kadın; ort. yaş: 61,44 ± 12,44) çalışmaya alındı. Hastalar CIN gelişmesine (CIN Dışı (n = 206) ve CIN grubuna (n = 21)) göre iki gruba ayrıldı. Bulgular: CSFP hastalarının% 9,25'inde (n = 21) CIN gözlendi. Serum U-II düzeyi CIN grubunda CIN olmayan gruba göre anlamlı derecede yüksek saptandı (6,79 ± 2,2 vs. 3 ± 1,29, p <0,001). Tüm nedenlere bağlı mortalite (7 (% 33,3) ve 24 (% 11,7), p = 0,013), kardiyovasküler ölüm (7 (% 33,3) ve 18 (8, % 7), p = 0,003) ve Majör olumsuz kardiyovasküler olaylar (MACE) (10 (% 47,6) vs. 46 (% 22,4), p: 0,011) CIN grubunda anlamlı derecede yüksekti. Ayrıca ileri koşullu lojistik regresyon analizi yapıldı ve CSFP'li hastalarda U-II (Oran oranı (OR) = 3,983;% 95 güven aralığı (CI): 2,25 ila 7,052; p <0,001) ve Mehran skorunun (OR = 1,228, %95 CI: 1,083-1,393, p = 0,001) bağımsız olarak CIN gelişimininin öngördürücülerinin olduğu saptandı. Sonuç: Yüksek serum U-II konsantrasyonları ve yüksek Mehran skorları CSFP hastalarında bağımsız olarak CIN gelişimi ile ilişkili bulunmuştur. Bir yıllık klinik takipte, tüm nedenlere bağlı ölüm, kardiyovasküler ölüm ve MACE bulguları CIN grubunda anlamlı derecede yüksek saptandı, ancak inme ve miyokard infarktüsü oranları her iki grupta da benzer bulundu.

🔖

Cite This Article

HUYUT, M. (2019). The Relationship Between Serum Urotensin II Level and Contrast-Induced Nephropathy and One-year Clinical Follow-up Findings in Patients with Coronary Slow Phenomenon Undergoing Percutaneous Coronary Intervention. Sakarya Tıp Dergisi, Cilt: 9 - Sayı: 3, 442–454. https://ajindex.com/articles/261300

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Hawkins BM, Stavrakis S, Rousan TA, Abu-Fadel M, Schechter E. Coronary slow flow--prevalence and clinical correlations. Circ J. 2012;76(4):936-42
  2. Rezkalla SH, Stankowski RV, Hanna J, Kloner RA. Management of No-Reflow Phenomenon in the Catheterization Laboratory. JACC Cardiovasc Interv. 2017 Feb 13;10(3):215-223. doi: 10.1016/j.jcin.2016.11.059
  3. Chaudhry MA, Smith M, Hanna EB, Lazzara R. Diverse spectrum of presentation of coronary slow flow phenomenon: a concise review of the literature. Cardiol Res Pract. 2012;2012:383181
  4. Yarlioglues M, Yalcinkaya D, Celik IE, Duran M. CHA2DS2VASc Score and Coronary No-Reflow Phenomenon. Angiology. 2019 May 23:3319719851698. doi: 10.1177/0003319719851698
  5. Kelly RF, Sompalli V, Sattar P, Khankari K. Increased TIMI frame counts in cocaine users: a case for increased microvascular resistance in the absence of epicardial coronary disease or spasm. Clin Cardiol 2003;26:319–22
  6. Quisi A, Alıcı G. The relationship between serum rheumatoid factor level and no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. J Clin Lab Anal. 2018 Nov;32(9):e22598. doi: 10.1002/jcla.22598
  7. Jaffe R, Dick A, Strauss BH. Prevention and treatment of microvascular obstruction-related myocardial injury and coronary no-reflow following percutaneous coronary intervention: a systematic approach. JACC Cardiovasc Interv. 2010;3:695‐704
  8. Brosh D, Assali AR, Mager A, Porter A, Hasdai D, Teplitsky I, et al. Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality. Am J Cardiol. 2007;99:442‐445
  9. Silvain J, Collet JP, Montalescot G. Contrast-induced nephropathy: the sin of primary percutaneous coronary intervention? Eur Heart J. 2014;35(23):1504-1506
  10. Caruso M, Balasus F, Incalcaterra E, Ruggieri A, Evola S, Fattouch K, et al. Contrast-induced nephropathy after percutaneous coronary intervention in simple lesions: risk factors and incidence are affected by the definition utilized. Intern Med. 2011;50(9):983-989
  11. Sadat U. Radiographic contrast-media-induced acute kidney injury: pathophysiology and prophylactic strategies. ISRN Radiol. 2013;2013:496438
  12. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002;105:2259– 64
  13. McCullough PA, Wol